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Abstract
Background: Metallothionein 3 (MT3) inhibits growth in a variety of cell types. We measured
MT3 gene expression by RT-PCR, and DNA methylation in the MT3 promoter by combined
bisulphite restriction analysis, in four oesophageal cancer cell lines and the resected oesophagus
from 64 patients with oesophageal squamous cell carcinoma (SCC).
Results: MT3 expression was not detected in one of the four oesophageal cell lines. The MT3
promoter was methylated in all of the oesophageal cell lines, but the degree of methylation was
greater in the non-expressing cell line. After treatment with 5-aza-2'-deoxycytidine there was a
reduction in the degree of methylation, and an increase in MT3 expression, in each of the cell lines
(p < 0.01). Methylation was detected in 52% (33 of 64) of primary SCC and 3% (2 of 62) of
histologically normal resection margins. MT3 expression was measured in 29 tumours, 17 of which
had methylation of MT3. The expression of MT3 was significantly less in the methylated tumours
compared to either the unmethylated tumours (p = 0.03), or the matched margin (p = 0.0005).
There was not a significant difference in MT3 expression between the tumour and the margin from
patients with unmethylated tumour. No correlations were observed between methylation of MT3
and survival time, patient age, gender, smoking or drinking history, tumour stage, volume, or lymph
node involvement.
Conclusion: We conclude that MT3 expression is frequently down-regulated in oesophageal SCC,
by DNA methylation, but that this is not a prognostic indicator.
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Background
The metallothioneins (MT) are a group of low molecular
weight, cysteine-rich intracellular proteins that are
involved in maintaining intracellular metal homeostasis
by binding transition metals such as zinc and copper.
There are 10 functional isoforms of MTs described, which
are divided into 4 classes, designated MT1 – 4, on the
basis of small differences in protein sequence and charge
characteristics [1,2]. The MTs have been proposed to play
an important role in protecting against DNA damage,
apoptosis and oxidative stress [3].
Metallothionein 3 (MT3) was first identified as a growth
inhibitory factor, expressed in normal brain, which inhib-
ited the survival of neurones in culture and also neurite
formation [4]. Subsequent studies using glial [5] or
tumour[6-8] cells, stably transfected with MT3, showed
that its endogenous over-expression could inhibit cell
growth. More recently, down-regulation of MT3  was
reported as one of 17 changes in gene expression which
was most likely to be associated with metastasis and poor
clinical outcome in a range of solid tumours [9]. One
mechanism for reducing gene expression is methylation
of the CpG island when present in the promoter region of
the gene [10]. Methylation of the MT3 promoter has been
observed and has been suggested to cause reduced expres-
sion in gastric cancer [11].
The levels of MT3 expression, the frequency of MT3 meth-
ylation, and correlations between MT3 methylation and
clinical parameters, have not been investigated in
oesophageal squamous cell carcinoma (SCC). In this
study we used combined bisulfite restriction analysis
(COBRA) [12] to estimate the frequency of methylation at
specific sites within the MT3  promoter in oesophageal
cancer cell lines, and investigated the relationship
between methylation and its expression by quantitative
real-time RT-PCR. We then measured MT3 gene expres-
sion and the frequency of MT3 methylation in primary
oesophageal SCCs and, when available, the histologically
normal, proximal resection margin from those patients.
Results
Methylation analysis of MT3 in normal lymphocytes and 
oesophageal cell lines
The methylation status of the MT3 CpG island was meas-
ured by COBRA within 3 overlapping regions (Figure 1).
Complete digestion of the COBRA PCR product indicated
methylation at one or more of the BstUI sites within that
region of all alleles. Incomplete digestion indicated meth-
ylation at one or more of the BstUI sites within that region
of some but not all alleles.
COBRA was performed on the bisulphite modified lym-
phocyte DNA from 19 different normal donors without
any known cancers or other genetic abnormalities. In each
of these donor lymphocytes samples an average of two
percent (± 1% SD) of molecules were methylated at site 12
in the R1 region, located in intron 1. There was no evi-
dence of methylation at any of the other sites analysed by
COBRA in the R1 and the R2 regions (data not shown).
COBRA was performed on the oesophageal cancer cell
lines OE19, OE21, OE33 and TE7, cultured with or with-
Schematic diagram of the MT3 promoter Figure 1
Schematic diagram of the MT3 promoter. The diagram was generated by downloading the MT3 CpG island genetic ele-
ment with the addition of 200 bases upstream from http://genome.ucsc.edu/, using the Human July 2003 Freeze. The location 
of 5' UTR (), exon 1 and exon 2 (■ ) of MT3 (NM_005954) are shown. Each vertical line represents a CpG. The arrows rep-
resent the location of the 12 BstUI restriction enzyme sites analysed. The regions amplified for the 3 COBRA PCRs, R1, R2 
and R3, are shown.Molecular Cancer 2005, 4:42 http://www.molecular-cancer.com/content/4/1/42
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out the DNA demethylation drug 5-aza-2'-deoxycytine
(aza-dC) (Figure 2). Complete digestion of each of the 3
regions was observed for OE33. For TE7, incomplete
digestion was observed in the R1 and R2 regions, whilst
complete digestion was observed in R3 region. Incom-
plete digestion was observed in each of the 3 regions for
OE21. For OE19, no digestion was observed in the R2
region, but incomplete digestion was observed in the R1
and R3 regions. The frequency of methylation at any BstUI
site within each of the regions, R1, R2 or R3, was esti-
mated in the oesophageal cell lines (Table 1). The fre-
quency of methylation in each region varied from cell line
to cell line, and the frequency of methylation in a given
cell line varied from region to region. We then estimated
the frequency of methylation at each BstUI site within a
region (Table 2). We observed that the frequency of meth-
ylation at each BstUI site within a region varied for a given
cell line and varied between cell lines.
Re-expression of the MT3 after 5-aza-2'-deoxycytine 
treatment
To determine the relationship between methylation and
transcription of the MT3 gene, we measured the expres-
sion of MT3 by RT-PCR in 4 oesophageal cell lines, OE19,
OE21, OE33 and TE7, cultured in the presence or absence
of aza-dC (Figure 3). MT3 expression was undetectable in
the completely methylated cell line OE33. Low levels of
MT3 were measured in the partially methylated cell lines
OE19, OE21 and TE7. Demethylation treatment with aza-
dC reduced the frequency of methylation both within and
between different regions for all cell lines provided that
the intial frequency of methylation was ≥ 10 %. Demeth-
ylation treatment did not completely demethylate all the
cells in culture. The expression of MT3 was significantly
increased following aza-dC treatment in each of the
oesophageal cell lines (p < 0.01). The increase in MT3
expression induced by aza-dC was significantly less in the
The MT3 COBRA on regions 1 (A), 2 (B) and 3 (C) for the  oesophageal cell lines with or without treatment with Aza- dC Figure 2
The MT3 COBRA on regions 1 (A), 2 (B) and 3 (C) 
for the oesophageal cell lines with or without treat-
ment with Aza-dC. The COBRA was performed on the 
oesophageal cell lines following 72 to 96 hrs of treatment 
with either 1 µM aza-dC (+) or vehicle (-). M, molecular 
weight marker.
The expression of MT3 in oesophageal cell lines Figure 3
The expression of MT3 in oesophageal cell lines. A) 
MT3 expression in the oesophageal cell lines grown for 72 to 
96 h with either 1 µM aza-dC (■ ) or vehicle (). Results are 
the average of triplicate values ± SD, normalised to that of 
PBGD. B) Representative example of gel electrophoresis of 
the MT3 and PBGD RT-PCR products for the cell lines fol-
lowing treatment with either 1 µM aza-dC (+) or vehicle (-).Molecular Cancer 2005, 4:42 http://www.molecular-cancer.com/content/4/1/42
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OE33 cell line compared to the OE19, OE21 or TE7 (p =
0.02).
Methylation and expression of MT3 in oesophageal SCC
The frequency of MT3  methylation was measured in
resected primary tumour and, when available, the proxi-
mal resection margin from 64 patients with oesophageal
SCC. From each sample the R1 and R2 regions of the MT3
CpG island were amplified by PCR and then analysed for
methylation by COBRA. As with the lymphocyte samples,
low levels of methylation at BstUI site 12 in the R1 region
were observed in all the histologically normal margins
and the tumour samples from these patients. Thus, this
ubiquitous low level of methylation was not considered
in the subsequent analysis. Methylation of the R1 region
was observed in 33 (52%) and of the R2 region in 10
(16%) of the tumour samples. All samples that were
methylated in the R2 region were also methylated in the
R1 region. No correlations were observed between patient
age, gender, smoking or drinking history, tumour, vol-
ume, or lymph node involvement and the methylation of
MT3 (Table 3). Methylation of the R2 region was observed
in none of the 62 proximal resection margin tissues avail-
able, whilst methylation of the R1 region was observed in
2 (3%).
MT3 gene expression was analysed by quantitative real-
time RT-PCR in 29 of the primary tumours and their
matched non-cancerous proximal resection margins for
which RNA was available. MT3 was methylated in 17 of
these tumours, and unmethylated in 12. The MT3 expres-
sion was normalized to that of ACTB. The expression of
MT3 was significantly less in the tumours in which the
promoter was methylated compared to those in which it
was unmethylated (Figure 4, p = 0.03). MT3 expression in
methylated tumours was significantly less than that of the
matched margin (p = 0.0005). There was not a statistically
significant difference in expression between the tumour
and matched margin from patients in whom the tumour
was unmethylated.
Survival data was available for 41 patients, 19 with an
unmethylated tumour, 22 methylated. There was no dif-
ference between these 2 groups with respect to the time
since operation (unmethylated: range 3 – 22 months,
median 20 months; methylated: range 1 – 22 months,
median 21 months). There were 5 deaths in the unmeth-
ylated and 4 in the methylated group (P = 0.7). There was
no difference in the survival time following operation,
with deaths in the unmethylated group occurring 3, 13,
13, 17 and 18 months post-operatively, compared to 1, 4,
8 and 22 months in the methylated group.
Discussion
In this study we investigated the expression of MT3 and its
control by DNA methylation in oesophageal SCC. We
measured methylation of MT3 by COBRA in three sepa-
rate regions of its promoter, and gene expression by quan-
titative real-time RT-PCR. In the oesophageal cell line
OE33, which had complete methylation at all the CpG
sites analysed, there was also complete transcriptional
silencing of the MT3 gene. In a further 3 cell oesophageal
cancer cell lines, each of which had partial methylation,
there was a partial but not complete reduction in gene
Table 1: The frequency of methylation of any BstUI site within a region, in oesophageal cell lines. The estimated frequency of 
methylation of any BstUI site within R1, R2 or R3, in the oesophageal cancer cell lines treated without (-) or with (+) with 1 µM aza-dC, 
where ∆ is the change in methylation frequency. The results are from a single, representative experiment.
OE19 OE21 OE33 TE7
-+∆ -+∆ -+∆ -+∆
R1 32% 23% -10% 93% 57% -37% 97% 37% -60% 88% 33% -55%
R2 6% 6% 0% 15% 10% -5% 96% 32% -64% 51% 19% -32%
R3 73% 30% -43% 97% 40% -57% 95% 51% -45% 100% 37% -63%
Table 2: The frequency of methylation of any BstUI site within R1, in oesophageal cell lines. The estimated frequency of methylation at 
each BstUI site of R1 in the oesophageal cancer cell lines treated without (-) or with (+) with 1 µM aza-dC, where ∆ is the change in 
methylation frequency. The results are from a single, representative experiment.
OE19 OE21 OE33 TE7
-+∆ -+∆ -+∆ -+∆
9/10 4% 5% 1% 34% 18% -16% 60% 13% -47% 36% 9% -27%
11 7% 6% -1% 88% 48% -40% 85% 16% -69% 55% 13% -42%
12 30% 21% -10% 76% 48% -29% 91% 34% -57% 82% 30% -52%Molecular Cancer 2005, 4:42 http://www.molecular-cancer.com/content/4/1/42
Page 5 of 9
(page number not for citation purposes)
expression. Treatment of each of these cell lines with aza-
dC, which reduced methylation, resulted in an increase in
gene expression.
In those the cell lines which had partial methylation, the
amount of methylation could vary between contiguous
CpGs in the same cell line, and could vary in particular
CpGs between cell lines. Thus, a particular CpG which
might be unmethylated in one cell line could be partially
or completely methylated in other cell lines expressing
similar levels of MT3. This is consistent with the reported
variability of methylation of the p16 CpG island in pri-
mary human mammary epithelial cells during escape
from growth arrest [13], and the O6-methylguanine-DNA
methyltransferase gene in human cell lines [14]. The sig-
nificance of this finding is that methods for the measure-
ment of DNA methylation such as methylation specific
PCR (MSP) which analyse methylation at one or two
CpGs only may misrepresent the methylation pattern of a
region. In addition these methods would mislead if they
probed CpGs with low levels of methylation in all tissues
analysed, such as the site 12 in intron 1 in our analysis of
MT3. This was methylated in normal lymphocytes and
normal oesophageal tissue, as well oesophageal SCC,
even though other CpGs were unmethylated and gene
expression was high.
In order to show the relationship between methylation
within the regions studied and MT3 gene expression, we
incubated cultures of the oesophageal cell lines for
approximately two cell divisions with aza-dC, a potent
inhibitor of DNA methyltransferase. Because the rate of
division varied for each of the cell lines, we determined
the length of time required for each of the cell lines to
divide twice in the presence of aza-dC using PKH-26 label-
ling [15]. This stable red fluorescent dye inserts into the
cytoplasmic membrane, and is distributed equally
amongst each of the daughter cells at the time of cell divi-
sion, such that the mean fluorescence intensity of the cell
population is halved with each cell division. As expected,
treatment with aza-dC for two cell divisions did not com-
pletely demethylate the cell lines. This is because it is only
newly synthesised strands which are demethylated, so if in
a cell a particular region of DNA is completely methylated
on both alleles, after 2 divisions only 75% of the alleles
will be demethylated. We found that there was a signifi-
cant reduction in the amount of methylation at each of
the methylated sites analysed following drug treatment.
Interestingly, the amount of the reduction varied between
different CpG sites within a cell line, and varied from cell
line to cell line at a given site. The reasons for this cell line
and regional variation in the extent of demethylation are
unknown.
Previous studies have shown that the methylation of only
a subset of available CpG sites within a region can be suf-
ficient to reduce transcription [16-18,13], with a greater
reduction in transcription as the density of CpG methyla-
Table 3: The incidence of MT3 methylation for the 64 patients with oesophageal SCC.
n Unmethylated Methylated
Male 45 22 23
Female 19 9 10
Age, median (range) 57 (42 – 76) 57 (46 – 76) 58 (42 – 70)
Males 57 (42 – 70) 54 (46 – 68) 57 (42 – 70)
Females 62 (49 – 76) 63 (49 – 76) 61 (50 – 68)
Tumour volume (cm3), median (range) 57 (4 – 300) 54 (4 – 300) 60 (4 – 225)
Histological differentiation
Well/moderate 57 28 29
P o o r 422
Not recorded 3 3 0
Tumour stage
T1N0M0 3 1 2
T2N0M0 9 5 4
T2N1M0 3 2 1
T2N2M0 1 1 0
T3N0M0 29 13 16
T3N1M0 9 6 3
T3N2M0 1 0 1
T3N2M1 1 0 1
T4N0M0 2 2 0
T4N0M1 1 0 1
T4N1M0 2 1 1
Not recorded 3 0 3Molecular Cancer 2005, 4:42 http://www.molecular-cancer.com/content/4/1/42
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tion increases [19]. Complete methylation of all the sites
in the regions which we studied correlated with lack of
any gene expression, while methylation of only a subset of
sites correlated with some MT3 expression, and the fur-
ther reduction in methylation resulting from demethyla-
tion with aza-dC always correlated with an increase in
MT3 expression. In this study we evaluated MT3 expres-
sion only by RT-PCR, because an antibody specific for the
MT3 protein was not commercially available. However,
previous studies have shown that when the MT3 transcript
was able to be detected the protein was also detectable
[20,21,7,8].
Our interest in MT3  came from a report that solid
tumours with a specific pattern of expression of 17 genes,
including down-regulation of MT3, were most likely to be
associated with metastasis and poor outcome [9].
Oesophageal SCC is an aggressive disease with a 5 year
survival of about 20%, death most commonly due to sec-
ondaries. Molecular markers which assist in predicting
metasases might help to tailor treatment options better.
MT3  was first identified as a growth inhibitory factor
which decreased the survival of neuronal cultures [4].
Subsequent studies using stably transfected cell lines
showed that up-regulation of MT3 was growth inhibitory
in some, but not all, cell lines [6-8].
The reported role of MT3 in carcinogenesis is unclear. In
gastric carcinomas MT3 expression was found to be mark-
edly reduced, but there was no indication of any relation-
ship to outcome in this report [22]. In contrast, levels of
MT3 protein were shown to be elevated in bladder [20]
and breast carcinomas [21]. This elevated expression was
a poor prognostic indicator, being associated with
increased tumour stage in bladder carcinoma, and poor
disease outcome in some breast carcinomas. In our series
of 64 patients with oesophageal SCC we found a degree of
methylation in 52% of primary tumours and 3% of the
histologically normal proximal resection margin. We
observed that MT3 expression was frequently down-regu-
lated in primary oesophageal SCC when compared to nor-
mal mucosa, and significant down-regulation was most
commonly observed in those tumours that were methyl-
ated for MT3, and not unmethylated tumours. Interest-
ingly, 3 tumours which had methylated DNA also had
normal expression of MT3. This might reflect a hetero-
zygous pattern of methylation, with only one allele meth-
ylated, or a mixed tumour cell population containing
some cells which were methylated and some which were
not. The techniques used in this study could not distin-
guish between these possibilities. Also, 3 patients with
unmethylated DNA had low levels of MT3  expression,
perhaps reflecting mutation or other change in the
tumour. We found no relationship between methylation
status and survival in the subset of patients for whom data
were obtainable, suggesting that in these patients there
would also be no relationship between gene expression
and survival. Methylation and reduced expression of MT3
was also not associated with tumour stage or tumour size.
Thus a change in MT3 expression by itself does not appear
to favour increased tumour growth, and methylations sta-
tus is not associated with survival, in patients with
oesophageal SCC.
Conclusion
We have shown that the MT3 promoter has a heterogene-
ous pattern of methylation in oeosphageal cancer cell
lines, and is associated with a reduction in the gene
expression. In resected oesophageal SCC tissue MT3
expression was frequently down-regulated, most com-
monly in those tumours in which the promoter region
was methylated. Methylation or down-regulation of MT3
did not correlate with and patient age, gender, smoking or
drinking history, tumour stage, volume, lymph node
involvement, or patient survival. MT3 methylation does
not show promise as a prognostic marker in patients with
oesophageal SCC.
Methods
Cell lines and tissue samples
The oesophageal cancer cell lines OE19, OE21, OE33 and
TE7 [23] were each cultured in RPMI 1640 supplemented
with 10% foetal bovine serum at 37°C with 5% CO2.
Whole blood was obtained from 19 normal donors, none
of whom had known cancers or genetic abnormalities.
Primary tumour and, when available, non-cancerous
MT3 expression in patient-matched tumour and non-cancer- ous proximal resection margin from patients with SCC of the  oesophagus Figure 4
MT3 expression in patient-matched tumour and non-
cancerous proximal resection margin from patients 
with SCC of the oesophagus. MT3 expression in the 
oesophageal tissue from patients with either methylated 
tumour (❍ ) or umethylated tumour (● ). Results are the 
average of triplicate values, normalised to that of ACTB. The 
grey bars represent the median expression for each group. 
The black lines link expression values of tissues from the 
same patient.Molecular Cancer 2005, 4:42 http://www.molecular-cancer.com/content/4/1/42
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proximal resection margin from 64 consecutive patients
undergoing oesophagectomy for SCC at the Department
of Thoracic Surgery, Fourth Hospital, Hebei Medical Uni-
versity, were collected into RNAlater (Ambion, Austin,
TX). Patient gender, age at the time of operation, smoking
and drinking history and tumour type, stage, volume, and
conventional histopathology were recorded. Survival data
were available for 41 patients. The study complied with
the appropriate institutional guidelines.
Demethylation of oesophageal cell lines by 5-aza-2'-
deoxycytine treatment
Re-expression studies for MT3 were performed on each of
the oesophageal cancer cell lines. To determine the culture
conditions required to achieve at least 2 cell divisions in
the presence or absence of 5-aza-2'-deoxycytine (aza-dC),
cells, labelled with PKH-26 (Sigma-Aldrich, Sydney, NSW,
Australia), were analysed by flow cytometry as described
previously [15]. The cells were treated for 72 (OE21, OE33
and TE7) or 96 (OE19) hr with culture medium contain-
ing either vehicle or 1 µM aza-dC (Sigma-Aldrich). The
medium was then replaced with fresh medium not con-
taining aza-dC, and the cells were incubated for a further
24 hr before harvesting.
Preparation of bisulphite modified DNA
Genomic DNA was isolated from normal donor lym-
phocytes, cultured cells, and RNAlater stabilized tissues.
Lymphocytes were isolated from whole blood using
Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). The
adherent cell lines were harvested by detaching the cells
from culture flasks using trypsin/EDTA. RNAlater stabi-
lized tissues were homogenised using disposable pestles
(Edwards Instruments, Narellan, NSW, Australia). Next,
the samples of lymphocytes, cultured cells, or RNAlater
stabilised tissues were digested for 3 days with proteinase
K and sodium dodecyl sulfate in TES, pH 8. The protein
was removed by NaCl precipitation. The DNA was precip-
itated with ethanol, and resuspended in TE, pH 8. The
DNA was bisulphite modified using a modification of the
method previously described [24]. Briefly, 2 µg of
genomic DNA was denatured by treatment with NaOH at
37°C for 15 min. The DNA was modified using a mixture
of 5 M sodium bisulfite (Sigma-Aldrich) and 0.72 µM
hydroquinone (Sigma-Aldrich) for 4 hr at 56°C. The sam-
ples were purified using Rapid PCR Purification System
(Marligen Biosciences, Ijamsville, MD), desulphonated
with NaOH for 15 min at 37°C, precipitated with ethanol
and sodium acetate, and resuspended in 50 µl of TE, pH 8.
Methylation analysis of the MT3 promoter by COBRA
Bisulphite modified DNA was amplified using primers
that amplified 3 overlapping regions, designated R1, R2
and R3 (Figure 1). The primers did not discriminate
between methylated and unmethylated alleles. The prim-
ers and PCR conditions were specific for bisulphite modi-
fied DNA, and did not amplify unmodified DNA. All
COBRA PCRs were performed in a volume of 50 µl con-
taining 2 µl of bisulphite modified DNA, 2 mM MgCl2,
0.2 mM dNTPs, 0.2 µM of forward and reverse primer,
and 0.5 U of HotStar Taq in 1 × PCR Buffer (Qiagen,
Hilden, Germany). The reactions were incubated in an
Eppendorf Mastercycler at 95°C for 15 min; then 45
cycles of 94°C for 1 min, 52, 54 or 60°C for 1 min, and
72°C for 1 min; and a 4 min final extension at 72°C
(Table 4). The PCR products (5 µl) were digested with 5
units of BstUI restriction enzyme (New England Biolabs,
Beverly, MA) in a final volume of 10 µl, for 4 hr at 60°C.
BstUI specifically digests at CGCG sites that are retained
after bisulphite modification when CpGs are methylated.
The unmethylated cytosines are deaminated to uracil by
the bisulphite reaction, then amplified as thymine in the
PCR reaction, and so are not digested by BstUI. The
digested PCR products were resolved on 2% agarose gels
and stained with ethidium bromide. The intensity of each
band was quantified and converted to nanograms of DNA
Table 4: Primer sequences and related information.
Primer Genome positiona Primer sequence Annealing temperature Product size
R1-forward +148 5'-AGTATYGTTATTTGTTGTTATTAGTTAAGT-3' 54°C 298 bp
R1-reverse +445 5'-TAAAATACCAAATCTCCCTATTCTC-3'
R2-forward -8 5'-GAGYGGGTTTYGGTAGTGTATATAT-3' 52°C 217 bp
R2-reverse +209 5'-TAAACRAACTTCTCCAAACAACTAAAC-3'
R3-forward +58 5'-GAAATGGAATAYGTTTTTTGTTAGTGAT-3' 60°C 427 bp
R3-reverse -369 5'-ACTCCRACRCACRCACTACATCT-3'
MT3-forward 5'-GACCTGCCCCTGCCCTTCTGGTGG-3' 69°C 219 bp
MT3-reverse 5'-GCTCCACACGGAGGGGTGCCTTCT-3'
ACTB-forward 5'-TTGCCGACAGGATGCAGAAG-3' 59°C 101 bp
ACTB-reverse 5'-CTTTCCAAGCGGAGCCATGTCTGG-3'
PBGD-forward 5'-CTTTCCAAGCGGAGCCATGTCTGG-3' 59°C 377 bp
PBGD-reverse 5'-CATGAGGGTTTTCCCGCTTGCAGA-3'
a Nucleotide position relative to the transcription start site.Molecular Cancer 2005, 4:42 http://www.molecular-cancer.com/content/4/1/42
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using Kodak ID Image Analysis Software (Kodak, Roches-
ter, NY). For each gel, 250 ng of the molecular weight
marker pUC19/Hpa II (GeneWorks, Adelaide, SA, Aus-
tralia) was used as a standard to determine DNA fragment
size and mass. Restriction maps for each digest were used
to determine the length of all possible fragments, and the
number of molecules in each band were determined by
multiplying the mass of DNA in each band by its' frag-
ment length. The frequency of methylation at each BstUI
site was then estimated by dividing the number of mole-
cules for each fragment by the total number of molecules
in the digest.
Analysis of MT3 expression by quantitative real-time RT-
PCR
Cell line RNA was isolated using the RNeasy kit (Qiagen)
with an on-column DNase I digestion. Tissue RNA was
isolated using Trizol (Invitrogen, Mount Waverly, VIC,
Australia) and treated with DNase I (Ambion). The cDNA
was synthesised from 2 µg of RNA using an M-MLV kit
(Invitrogen). Quantitative real-time RT-PCR was per-
formed on a RotorGene 2000 PCR thermocycler (Corbett
Research, Sydney, NSW, Australia). Triplicate reactions
were done using the appropriate PCR primers (Table 4)
and the Quantitect Sybr-Green PCR mix (Qiagen). The
PCR products were electrophoresed on 1.5 % agarose gels
and stained with ethidium bromide. The expression of
MT3 was normalized to that of either ACTB or PBGD [25].
Data analysis
Statistical analysis of expression of MT3 before and after
aza-dC treatment for each cell line was performed using
unpaired T-tests. Comparisons of the levels of MT3
between cell lines with or without aza-dC treatment were
performed using ANOVA with Tukey-Kramer multiple
comparisons test. The comparison of the volume of meth-
ylated and unmethylated tumours was performed using a
Kruskal-Wallis Test. The comparison of patients with or
without positive lymph nodes and methylation status was
performed using a Chi-squared test. The Mann-Whitney
test was used to compare MT3 expression in methylated
and unmethylated tumour. Comparisons of MT3 expres-
sion in tumour and margin were performed using Wil-
coxon matched-pairs sign-rank tests. Survival data were
analysed using Fisher's Exact Test. All statistics were per-
formed using InStat version 3.0a (GraphPad Software, San
Diego, CA).
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